Buy Oxycodone 30
Buy Oxycodone 30. ROXICODONE® (oxycodone hydrochloride tablets USP) is an opioid analgesic. Each tablet for oral administration contains 5 mg, 15 mg, or 30 mg of oxycodone hydrochloride USP. Oxycodone hydrochloride is a white, odorless crystalline powder derived from the opium alkaloid, thebaine.
This medication is consumed to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.
Hence ROXICODONE® tablets have been rated in open-label clinical trials in patients with cancer and nonmalignant pain. ROXICODONE® tablets are alike with adverse experiences similar to those seen with other opioids.
Moreover, serious adverse reactions that may be related to ROXICODONE® therapy in clinical use are those observed with other opioid analgesics and include respiratory depression, respiratory arrest, circulatory depression, cardiac arrest, hypotension, and/or shock (see OVERDOSE, WARNINGS).
The less severe adverse events seen on initiation of therapy with ROXICODONE® are also typical opioid side effects. These events are dose-dependent, and their frequency depends on the clinical setting, the patient’s level of opioid tolerance, and host factors specific to the individual. The most frequent of these include nausea, constipation, vomiting, headache, and pruritus.
In many cases, the frequency of adverse events during the initiation of opioid therapy may be minimized by careful individualization of starting dosage, slow titration, and the avoidance of large rapid swings in plasma concentration of the opioid. Many of these adverse events will abate as therapy is continued and some degree of tolerance is developed, but others may be expected to remain throughout therapy.
In all patients for whom dosing information was available (n=191) from the open-label and double-blind studies involving ROXICODONE®, the following adverse events were recorded in ROXICODONE® treated patients with an incidence ≥ 3%. In descending order of frequency, they were: nausea, constipation, vomiting, headache, pruritus, insomnia, dizziness, asthenia, and somnolence.